Targeting sphingolipid biosynthesis to enhance trisomy 21 cell health
Innovative approach to ameliorate cellular defects in trisomy 21 by targeting sphingolipid biosynthesis, specifically ceramide synthase, to improve cell fitness and nuclear morphology. Potentially beneficial for individuals with Down syndrome.
Overview
This research targets the improvement of cellular health in trisomy 21, a condition causing Down syndrome, by focusing on sphingolipid biosynthesis. The approach aims to alleviate cellular defects associated with aneuploidy without impacting the fitness of normal cells. By inhibiting ceramide synthase activity, the strategy seeks to ameliorate nuclear abnormalities and enhance proliferation in trisomy 21 fibroblasts, offering a promising avenue for clinical applications.
Technical specifications
The core of this research is a genetic approach to modulate the expression of ceramide synthases in human fibroblasts. Initial experiments using fumonisin B1 demonstrated significant suppression of nuclear abnormalities and improved proliferation in trisomic fibroblasts, while minimally affecting control cells. The focus is on CerS4, a highly expressed gene in trisomy 21 fibroblasts, with plans to knock down its expression and assess effects on nuclear morphology and cell proliferation.
Technology readiness level
This research is currently at Technology Readiness Level 3, with experimental proof of concept demonstrated in laboratory settings. Further validations are planned to advance the technology towards clinical relevance, particularly for Down syndrome intervention.
About University of Massachusetts Medical School
A public academic health sciences center within the University of Massachusetts system, it combines medical education, graduate training, and patient care with a strong research enterprise. Close integration with a major hospital system enables access to diverse patient populations, clinical data, and translational infrastructure, supporting industry‑sponsored studies and real‑world evaluation. Co‑located research core facilities and centralized contracting, IRB, and compliance support streamline collaboration, from early discovery through multicenter trials. The institution attracts significant NIH funding and competitive awards from other federal agencies and foundations. A dedicated technology transfer office manages IP, material transfer and licensing, and supports startup formation and corporate research agreements.
delivered to your inbox.